Avon restructuring charges
This article was originally published in The Rose Sheet
Executive Summary
Firm will take $80 mil.-$90 mil. charge in Q4 "for costs to accelerate the company's business transformation initiatives" in light of lower than expected results in Latin American markets, Avon tells analysts Dec. 7. Company expects Q4 sales to increase in mid-single digits, boosted by U.S. revenues that are trending up 8%-9%. Additional restructuring charges are possible in 2002. Nevertheless, initiatives, coupled with "underlying strength of our business fundamentals, should enable Avon to deliver double-digit growth in earnings per share and local currency sales next year," firm predicts...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.